Bauer T T, Ewig S, Marre R, Suttorp N, Welte T
HELIOS Clinic Emil v. Behring, Respiratory Diseases Clinic Heckeshorn, Berlin, Germany.
J Intern Med. 2006 Jul;260(1):93-101. doi: 10.1111/j.1365-2796.2006.01657.x.
The study was performed to validate the CURB, CRB and CRB-65 scores for the prediction of death from community-acquired pneumonia (CAP) in both the hospital and out-patient setting.
Data were derived from a large multi-centre prospective study initiated by the German competence network for community-acquired pneumonia (CAPNETZ) which started in March 2003 and were censored for this analysis in October 2004.
Out- and in-hospital patients in 670 private practices and 10 clinical centres.
Analysis was done for n = 1343 patients (n = 208 out-patients and n = 1135 hospitalized) with all data sets completed for the calculation of CURB and repeated for n = 1967 patients (n = 482 out-patients and n = 1485 hospitalized) with complete data sets for CRB and CRB-65.
None. 30-day mortality from CAP was determined by personal contacts or a structured interview.
Overall 30-day mortality was 4.3% (0.6% in out-patients and 5.5% in hospitalized patients, P < 0.0001). Overall, the CURB, CRB and CRB-65 scores provided comparable predictions for death from CAP as determined by receiver-operator-characteristics (ROC) curves. However, in hospitalized patients, CRB misclassified 26% of deaths as low risk patients. Availability of the CRB-65 score (90%) was far superior to that of CURB (65%), due to missing blood urea nitrogen values (P < 0.001).
Both the CURB and CRB-65 scores can be used in the hospital and out-patients setting to assess pneumonia severity and the risk of death. Given that the CRB-65 is easier to handle, we favour the use of CRB-65 where blood urea nitrogen is unavailable.
本研究旨在验证CURB、CRB和CRB-65评分在预测社区获得性肺炎(CAP)患者在医院和门诊环境中的死亡情况的有效性。
数据来源于德国社区获得性肺炎能力网络(CAPNETZ)于2003年3月启动的一项大型多中心前瞻性研究,并于2004年10月进行了此次分析的审查。
670家私人诊所和10个临床中心的门诊和住院患者。
对n = 1343例患者(n = 208例门诊患者和n = 1135例住院患者)进行分析,所有数据集均完成用于计算CURB,并对n = 1967例患者(n = 482例门诊患者和n = 1485例住院患者)重复分析,这些患者具有用于CRB和CRB-65的完整数据集。
无。通过个人联系或结构化访谈确定CAP患者的30天死亡率。
总体30天死亡率为4.3%(门诊患者为0.6%,住院患者为5.5%,P < 0.0001)。总体而言,CURB、CRB和CRB-65评分对CAP死亡的预测效果相当,这由受试者工作特征(ROC)曲线确定。然而,在住院患者中,CRB将26%的死亡患者误分类为低风险患者。由于血尿素氮值缺失,CRB-65评分的可获得性(90%)远优于CURB(65%)(P < 0.001)。
CURB和CRB-65评分均可用于医院和门诊环境中评估肺炎严重程度和死亡风险。鉴于CRB-65更易于使用,在无法获得血尿素氮的情况下,我们倾向于使用CRB-65。